K. G. Mitchell

The University of Texas MD Anderson Cancer Center

Papers

2

Total Citations

186

H-Index

2

About

Dr. K. G. Mitchell is a leading thoracic surgeon and translational researcher whose work bridges the frontiers of immunotherapy and minimally invasive surgery for non–small cell lung cancer (NSCLC). Her research centers on optimizing multimodal treatment strategies, particularly the integration of neoadjuvant immune checkpoint inhibitors with surgical resection. In a landmark 2022 study (94 citations), she demonstrated that combining nivolumab with ipilimumab before surgery yields promising pathological responses and manageable toxicity, reshaping perioperative protocols. Complementing this, her comprehensive 2019 analysis of robotic-assisted lobectomy (92 citations) established benchmarks for safety, oncologic efficacy, and recovery outcomes in advanced NSCLC. With over 90 citations on each of these pivotal works, Dr. Mitchell’s contributions have directly influenced clinical guidelines and surgical practice. Her work exemplifies the synergy between cutting-edge immunotherapy and precision surgery, offering patients improved survival and quality of life. A sought-after speaker and collaborator, she continues to drive innovation in thoracic oncology, mentoring the next generation of surgeon-scientists.

Research Focus

Key Achievements

2
H-Index
2
Papers
186
Total Citations
93
Avg Citations/Paper
🏆 Most Cited Paper
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancer
94 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 24
🏛 Institutions: The University of Texas MD Anderson Cancer Center

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago